F-star Therapeutics, Inc.
FSTXNASDAQHealthcare
$7.12
+$0.00(+0.00%)
Market Cap$156511128
P/E Ratio—
52W High$7.12
52W Low$2.07
F-star Therapeutics, Inc. (FSTX) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
FSTX · earnings · updated Jun 9, 2026
Latest Earnings
Q1 FY2023Report Date: Mar 22, 2023EPS Actual
$0.47
Est. -$0.39 · +220.5%
Revenue
—
Est. $0.00B
Fiscal Period
Q1 FY2023
FY ends December
Report Date
Mar 22, 2023
After Market Close
▲ Beat EPS✓ 1-Quarter EPS Beat Streak
FSTX reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$93.32
Rev. $1001.5B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$93.32
Rev. Est.$1001.5B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q2 FY2023 | May 8, 2023 | -$0.39 | — | — | — | — | — |
| ▲ Q1 FY2023 | Mar 22, 2023 | -$0.39 | $0.47 | +220.5% | — | $0.00B | — |
| ▼ Q4 FY2022 | Nov 10, 2022 | -$0.79 | -$0.84 | -6.3% | $0.00B | — | — |
| ▼ Q3 FY2022 | Aug 11, 2022 | -$0.58 | -$0.88 | -51.7% | — | — | — |
| ▲ Q2 FY2022 | May 10, 2022 | -$0.67 | -$0.57 | +14.9% | $0.00B | $0.00B | -13.0% |
| ▲ Q1 FY2022 | Mar 14, 2022 | -$0.11 | $0.48 | +536.4% | $0.02B | $0.00B | +1911.4% |
| ▲ Q4 FY2021 | Nov 10, 2021 | -$0.58 | -$0.52 | +10.3% | $0.00B | $0.00B | -6.7% |
| ▼ Q3 FY2021 | Aug 12, 2021 | -$0.74 | -$0.92 | -24.3% | — | $0.00B | — |
Q2 FY2023
May 8, 2023
EPS Actual
—
EPS Est.
-$0.39
EPS Surpr.
—
Revenue
—
Q1 FY2023
Mar 22, 2023Beat
EPS Actual
$0.47
EPS Est.
-$0.39
EPS Surpr.
+220.5%
Revenue
—
Q4 FY2022
Nov 10, 2022Miss
EPS Actual
-$0.84
EPS Est.
-$0.79
EPS Surpr.
-6.3%
Revenue
$0.00B
Q3 FY2022
Aug 11, 2022Miss
EPS Actual
-$0.88
EPS Est.
-$0.58
EPS Surpr.
-51.7%
Revenue
—
Q2 FY2022
May 10, 2022Beat
EPS Actual
-$0.57
EPS Est.
-$0.67
EPS Surpr.
+14.9%
Revenue
$0.00B
Q1 FY2022
Mar 14, 2022Beat
EPS Actual
$0.48
EPS Est.
-$0.11
EPS Surpr.
+536.4%
Revenue
$0.02B
Q4 FY2021
Nov 10, 2021Beat
EPS Actual
-$0.52
EPS Est.
-$0.58
EPS Surpr.
+10.3%
Revenue
$0.00B
Q3 FY2021
Aug 12, 2021Miss
EPS Actual
-$0.92
EPS Est.
-$0.74
EPS Surpr.
-24.3%
Revenue
—
No analyst estimates available for FSTX.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q1 FY2023 | Mar 22, 2023 | +220.5% | $7.12 | — | — |
| ▼ Q4 FY2022 | Nov 10, 2022 | -6.3% | $4.69 | $4.76 | +1.49% |
| ▼ Q3 FY2022 | Aug 11, 2022 | -51.7% | $6.62 | $6.57 | -0.76% |
| ▲ Q2 FY2022 | May 10, 2022 | +14.9% | $2.22 | $2.44 | +9.91% |
| ▲ Q1 FY2022 | Mar 14, 2022 | +536.4% | $2.99 | $2.77 | -7.36% |
| ▲ Q4 FY2021 | Nov 10, 2021 | +10.3% | $6.65 | $6.27 | -5.71% |
| ▼ Q3 FY2021 | Aug 12, 2021 | -24.3% | $6.61 | $6.71 | +1.51% |
| ▲ Q2 FY2021 | May 17, 2021 | +6.9% | $6.57 | $6.74 | +2.59% |
Q1 FY2023—
Report Date
Mar 22, 2023
EPS Beat/Miss
+220.5%
Price Before
$7.12
Price After
—
Q4 FY2022+1.49%
Report Date
Nov 10, 2022
EPS Beat/Miss
-6.3%
Price Before
$4.69
Price After
$4.76
Q3 FY2022-0.76%
Report Date
Aug 11, 2022
EPS Beat/Miss
-51.7%
Price Before
$6.62
Price After
$6.57
Q2 FY2022+9.91%
Report Date
May 10, 2022
EPS Beat/Miss
+14.9%
Price Before
$2.22
Price After
$2.44
Q1 FY2022-7.36%
Report Date
Mar 14, 2022
EPS Beat/Miss
+536.4%
Price Before
$2.99
Price After
$2.77
Q4 FY2021-5.71%
Report Date
Nov 10, 2021
EPS Beat/Miss
+10.3%
Price Before
$6.65
Price After
$6.27
Q3 FY2021+1.51%
Report Date
Aug 12, 2021
EPS Beat/Miss
-24.3%
Price Before
$6.61
Price After
$6.71
Q2 FY2021+2.59%
Report Date
May 17, 2021
EPS Beat/Miss
+6.9%
Price Before
$6.57
Price After
$6.74
Avg Beat Reaction-0.14%
Avg Miss Reaction+0.75%
Beat Rate5 / 8 quarters
Largest Move+9.91% (Q2 FY2022)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: FSTX ends December
F-star Therapeutics, Inc. (FSTX) most recently reported earnings on March 22, 2023 for Q1 FY2023, posting EPS of $0.47 — beating the analyst consensus of $-0.39 by +220.5%. The next FSTX earnings date is expected around September 1, 2026.
Each quarter, investors track FSTX earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. FSTX revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
FSTX's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
FSTX earnings · 5 questionsF-star Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. FSTX typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; FSTX historically reports after market close (AMC).
FSTX earnings datewhen is FSTX earningsFSTX next earnings datewhen does FSTX report earningsFSTX earnings calendar
▸ Source: FMP · F-star Therapeutics, Inc. SEC filings · US GAAP · F-star Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026